Antibiotics Act with vB_AbaP_AGC01 Phage against <i>Acinetobacter baumannii</i> in Human Heat-Inactivated Plasma Blood and<i> Galleria mellonella</i> Models

• Main Authors: Bartłomiej Grygorcewicz, Marta Roszak, Piotr Golec, Daria Śleboda-Taront, Natalia Łubowska, Martyna Górska, Joanna Jursa-Kulesza, Rafał Rakoczy, Bartosz Wojciuk, Barbara Dołęgowska
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: International Journal of Molecular Sciences
• Subjects: Acinetobacter baumannii; antibiotics resistance; bacteriophages; blood infection; Galleria mellonella
• Online Access: https://www.mdpi.com/1422-0067/21/12/4390
• ISSN: 1661-6596; 1422-0067

<b> </b>Increasing multidrug resistance has led to renewed interest in phage-based therapy. A combination of the bacteriophages and antibiotics presents a promising approach enhancing the phage therapy effectiveness. First, phage candidates for therapy should be deeply characterized. Here we characterize the bacteriophage vB_AbaP_AGC01 that poses antibacterial activity against clinical Acinetobacter baumannii strains. Moreover, besides genomic and phenotypic analysis our study aims to analyze phage–antibiotic combination effectiveness with the use of ex vivo and in vivo models. The phage AGC01 efficiently adsorbs to A. baumannii cells and possesses a bacteriolytic lifecycle resulting in high production of progeny phages (317 ± 20 PFU × cell⁻¹). The broad host range (50.27%, 93 out of 185 strains) against A. baumannii isolates and the inability of AGC01 to infect other bacterial species show its high specificity. Genomic analysis revealed a high similarity of the AGC01 genome sequence with that of the <i>Friunavirus</i> genus from a subfamily of Autographivirinae. The AGC01 is able to significantly reduce the A. baumannii cell count in a human heat-inactivated plasma blood model (HIP-B), both alone and in combination with antibiotics (gentamicin (GEN), ciprofloxacin (CIP), and meropenem (MER)). The synergistic action was observed when a combination of phage treatment with CIP or MER was used. The antimicrobial activity of AGC01 and phage-antibiotic combinations was confirmed using an in vivo larva model. This study shows the greatest increase in survival of G. mellonella larvae when the combination of phage (MOI = 1) and MER was used, which increased larval survival from 35% to 77%. Hence, AGC01 represents a novel candidate for phage therapy. Additionally, our study suggests that phages and antibiotics can act synergistically for greater antimicrobial effect when used as combination therapy.